论文部分内容阅读
目的:观察电灼联合5%咪喹莫特乳膏治疗尖锐湿疣疗效及安全性。方法:使用抛硬币法将84例患者随机分成治疗组(44例)和对照组(40例),治疗组使用电灼联合5%咪喹莫特乳膏治疗,对照组使用电灼联合重组人干扰素-2b凝胶治疗,对比分析这两组治疗效果及安全性。结果:治疗组复发率为9.09%,对照组复发率为27.50%,治疗组患者复发率明显低于对照组(P<0.05);治疗组有5例出现轻度红斑,2例轻度糜烂。对照组3例出现轻度瘙痒、灼痛。两组不良发生率比较差异无统计学意义(P>0.05)。停药后均可自行消退,不影响继续治疗。结论:电灼联合5%咪喹莫特乳膏治疗尖锐湿疣疗效明显及安全性较高,值得临床推广使用。
Objective: To observe the efficacy and safety of electrocautery combined with 5% imiquimod cream in the treatment of condyloma acuminatum. Methods: Totally 84 patients were divided into treatment group (44 cases) and control group (40 cases) by coin-tosting method. The treatment group was treated with electrocautery combined with 5% imiquimod cream. The control group was treated with electrocautery combined with recombinant human Interferon-2b gel treatment, comparative analysis of the two groups of treatment and safety. Results: The recurrence rate was 9.09% in the treatment group and 27.50% in the control group. The relapse rate in the treatment group was significantly lower than that in the control group (P <0.05). In the treatment group, 5 cases had mild erythema and 2 cases mild erosion. In the control group, mild itching and burning occurred in 3 cases. No significant difference between the two groups incidence of adverse reactions (P> 0.05). After withdrawal can be resolved on their own, does not affect the continued treatment. Conclusion: The combination of electrocautery combined with 5% imiquimod cream has obvious curative effect and high safety for the treatment of condyloma acuminatum, which is worthy of clinical application.